Is there a Bearish outlook for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) this week?

July 27, 2018 - By Jason Dias

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) LogoInvestors sentiment decreased to 0.95 in Q1 2018. Its down 1.13, from 2.08 in 2017Q4. It worsened, as 26 investors sold Achillion Pharmaceuticals, Inc. shares while 29 reduced holdings. 17 funds opened positions while 35 raised stakes. 107.48 million shares or 2.61% less from 110.36 million shares in 2017Q4 were reported.
Acadian Asset Mngmt Ltd reported 82,478 shares. Vanguard Gru Inc Inc reported 10.86 million shares or 0% of all its holdings. Manitoba – Canada-based Great West Life Assurance Company Can has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Moreover, Daiwa Securities Grp Incorporated has 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Nj State Employees Deferred Compensation Plan has 30,000 shares for 0.02% of their portfolio. Cwm Ltd Limited Liability Company holds 75 shares or 0% of its portfolio. Rock Springs Capital Mgmt Ltd Partnership has 2.25 million shares. Employees Retirement Association Of Colorado holds 0% or 27,160 shares. Deutsche Bancorporation Ag accumulated 1.65 million shares or 0% of the stock. Florida-based State Board Of Administration Of Florida Retirement Systems has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). 100,300 are held by Spark Inv Ltd Liability Co. Zurcher Kantonalbank (Zurich Cantonalbank) reported 2,980 shares. State Street has 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 5.92M shares. Jacobs Levy Equity Management stated it has 151,400 shares or 0.01% of all its holdings. Manufacturers Life The holds 0% or 104,193 shares.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Coverage

Among 3 analysts covering Achillion Pharmaceuticals (NASDAQ:ACHN), 0 have Buy rating, 0 Sell and 3 Hold. Therefore 0 are positive. Achillion Pharmaceuticals has $500 highest and $3.5 lowest target. $4’s average target is 45.99% above currents $2.74 stock price. Achillion Pharmaceuticals had 4 analyst reports since February 8, 2018 according to SRatingsIntel. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) earned “Hold” rating by FBR Capital on Friday, February 23. The firm has “Hold” rating given on Wednesday, February 7 by FBR Capital. The stock has “Hold” rating by Barclays Capital on Monday, May 21. Below is a list of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) latest ratings and price target changes.

21/05/2018 Broker: Barclays Capital Rating: Hold New Target: $5.0000 Upgrade
23/02/2018 Broker: FBR Capital Rating: Hold Maintain
07/02/2018 Broker: FBR Capital Rating: Hold New Target: $3.5 Initiate
08/02/2018 Broker: B. Riley & Co Rating: Neutral New Target: $3.5 Initiates Coverage On

The stock increased 1.11% or $0.03 during the last trading session, reaching $2.74. About 843,005 shares traded. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 13.49% since July 27, 2017 and is downtrending. It has underperformed by 26.06% the S&P500.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. The company has market cap of $379.05 million. The Company’s drug candidates for treating chronic hepatitis C virus infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. It currently has negative earnings. The firm is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors.

More important recent Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) news were published by: Nasdaq.com which released: “Achillion Initiates Phase I First-in-Human Study of ACH-5548, a Third Oral Small Molecule Inhibitor of Complement …” on July 10, 2018, also Seekingalpha.com published article titled: “Achillion Pharmaceuticals – Biotech Gold For The Price Of Dirt”, Streetinsider.com published: “Achillion Pharma (ACHN) Commences Phase I First-in-Human Study of ACH-5548” on July 10, 2018. More interesting news about Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) was released by: Seekingalpha.com and their article: “Achillion Is A Worthwhile Biotech Speculation” with publication date: July 12, 2018.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.